Randomized Pragmatic Trial of the Comparative Effectiveness of Chicken Egg-Based Inactivated, Mammalian Cell Culture-Based Inactivated, and Recombinant Protein Quadrivalent Seasonal Influenza Vaccines in United States Military Health System Beneficiaries
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf503 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Rhonda E Colombo und 32 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Scienc…. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Influenza is a major cause of morbidity and mortality worldwide. The Pragmatic Assessment of Influenza Vaccine Effectiveness (VE) in the Department of Defense (PAIVED) study compared the relative VE (rVE) of 2 licensed influenza vaccines (cell culture-based inactivated influenza vaccine [ccIIV] and recombinant influenza vaccine [RIV]) to egg-based inactivated influenza vaccine (eIIV).
Methods
Between 2018 and 2021, PAIVED randomized (1:1:1) eligible Military Health System beneficiaries to receive eIIV, ccIIV, or RIV during an influenza season. Participants received weekly surveys querying influenza-like illness (ILI); those reporting ILI completed an online symptom diary, were interviewed by research staff, and underwent nasal swab collection. Laboratory-confirmed influenza was the primary outcome. Immunogenicity assessment was conducted in a subset of participants.
Results
Among 15 432 participants, influenza was identified in 87/5130 (1.7%) ccIIV recipients, 79/5154 (1.5%) RIV recipients, and 69/5148 (1.3%) eIIV recipients during their season of enrollment. rVE of ccIIV compared to eIIV was −27% (95% confidence interval [CI], −73%, 8%), and rVE of RIV compared to eIIV was −14% (95% CI −58%, 17%). RIV (N = 375) recipients were more likely to seroconvert (4-fold increase) than those who received eIIV (N = 355) (A/H1N1: 49.1% vs 29.0%; A/H3N2: 71.2% vs 30.4%; B/Victoria 24.5% vs 13.8%; B/Yamagata 17.1% vs 5.4%; P < .001 for all). ccIIV (N = 357) recipients were more likely to seroconvert only against A/H3N2 compared with eIIV recipients (44.0% vs 30.4%) (P < .001).
Conclusions
Significant differences in VE were not detected comparing egg-based to non-egg–based influenza vaccines, although immunogenicity differences were observed; low influenza case numbers impacted VE estimate precision. Trial Registration ClinicalTrials.gov NCT03734237.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Department of Medicine, Madigan Army Medical Center, Tacoma, Washington, USA.
- Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
- Carl R. Darnall Army Medical Center, Fort Cavazos, Texas, USA.
ORCID-Profile: Rhonda E Colombo, Stephanie A Richard, Christina Schofield, Tahaniyat Lalani, Ana E Markelz, Laurie Housel, Adam Saperstein, Alan Williams, Bruce McClenathan, Srihari Seshadri, Anthony Fries, John H Powers Iii, Robert J O'Connell, Christian L Coles
Förderung
- NCI NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- Defense Health Agency Immunization Healthcare Division
- Inter-Agency
- Defense Health Program
- National Institutes of Health Clinical Center
- Uniformed Services University of the Health Sciences
Zitieren
APA
Colombo, R. E., Richard, S. A., Schmidt, K., Schofield, C., Ganesan, A., Campbell, W., Hrncir, D., Lalani, T., Mende, K., Markelz, A. E., Berjohn, C. M., Housel, L., Becher, D., Zell, E. R., Ewing, D., Sundaram, A. K., Modi, J. R., Saperstein, A., Tilley, D. H., …, & PAIVED Study Group (2025). Randomized Pragmatic Trial of the Comparative Effectiveness of Chicken Egg-Based Inactivated, Mammalian Cell Culture-Based Inactivated, and Recombinant Protein Quadrivalent Seasonal Influenza Vaccines in United States Military Health System Beneficiaries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf503
Vancouver
Colombo RE, Richard SA, Schmidt K, Schofield C, Ganesan A, Campbell W, et al. Randomized Pragmatic Trial of the Comparative Effectiveness of Chicken Egg-Based Inactivated, Mammalian Cell Culture-Based Inactivated, and Recombinant Protein Quadrivalent Seasonal Influenza Vaccines in United States Military Health System Beneficiaries. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf503
BibTeX
@article{Colombo2025,
author = {Colombo, Rhonda E and Richard, Stephanie A and Schmidt, Kat and Schofield, Christina and Ganesan, Anuradha and Campbell, Wesley and Hrncir, David and Lalani, Tahaniyat and Mende, Katrin and Markelz, Ana E and Berjohn, Catherine M and Housel, Laurie and Becher, Dorothy and Zell, Elizabeth R and Ewing, Daniel and Sundaram, Appavu K and Modi, Jitendrakumar R and Saperstein, Adam and Tilley, Drake H and Williams, Alan and McClenathan, Bruce and Collins, Limone and Spooner, Christina and Seshadri, Srihari and Fries, Anthony and Maves, Ryan C and Powers Iii, John H and O'Connell, Robert J and Pollett, Simon D and Simons, Mark P and Coles, Christian L and Burgess, Timothy H and PAIVED Study Group, PAIVED Study Group},
title = {Randomized Pragmatic Trial of the Comparative Effectiveness of Chicken Egg-Based Inactivated, Mammalian Cell Culture-Based Inactivated, and Recombinant Protein Quadrivalent Seasonal Influenza Vaccines in United States Military Health System Beneficiaries},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf503}
}
EUVIMED